Exact Sciences is exhibiting bullish tendencies at present, but it's critical to anticipate a substantial correction upon touching, or descending below, the 0.618 Fibonacci retracement level. The stock is likely to retreat to around $70, a significant support level we've observed. The patterns in play – the AB=CD pattern and a yet unconfirmed bearish bat pattern –...
Based on my previous technical analysis where Exact Sciences exhibited bullish tendencies but warned of a possible substantial correction around the $70 level, we now find ourselves at a critical junction. Two possible scenarios could unfold from here: a bearish three drives pattern leading to a bounce back to around $123 or a continuation of the downtrend...
Correction could now be over @ 62% retrace.
Looking for a move up to the upper trend line into 2027 based on previous cycles.
+ Momentum divergence at the c wave low suggests energy is building for the next move higher.
Trendchanges and its author are not registered financial advisors. Everything that is documented by Trendchanges and its author within the...
Fundamentally The Company have a really good quarterly results and is looking cheap at this price. Technically we can see buying pressure from good area of support. Price might go as high as 84.50/85.50 $ before next quarterly results.
If you want to know where price is going to be, look for the history. Will this break out of this range and head higher or flush below?
if it can close above 65 this week, I would keep an eye on it above 68. It moves quickly so a news could push this over/under.
Long via commons and options. stop loss = 63.0
Exact Sciences is a biotech stock that is overpriced.
It's time to sell
We touched 3 times the resistance line of a rising wedge pattern, impulsive wave pattern, and RSI 71 weekly overbought zone, the Q2 doesn't seem good.
A leg down to 60$ retesting 69$ which is the resistance line of a rising wedge dropping below 40$ and based on the Q2 announcement either...
Exact Sciences is a biotech stock showing high relative strength.
Following a 50% jump in January, the stock is tightening with pullbacks getting shallower from left to right.
This is a sign of seller digestion which we often see before a new breakout to the upside.
EXAS is also finding support at key moving averages which appear to be holding up the stock.
I...
The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137! How many insiders bought any shares at $40? NONE! BIG ZERO! The technical chart is obvious. On the fundamentals:
Revenue of company...
Nice bat forming at a historical Ice line form way back when. Divergences are forming on other oscillators but Class A reversal divergence is on the RSI
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate,...
Exact Sciences Corp. is a molecular diagnostics company specialising in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other...
Strong support at $90. However, down trend line also is strong. Weakening momentum as confirmed by the MACD indicator.
Likely to see the down trendline holding down prices. Will have to see which Demand Zone (green boxes) provides the support. If it doesn't and it breaks below the $90 support, then it might fall to $75-$80. Definitely don't want to see it fall...
EXAS just under doubled revenue from 2019 to 2020 and is trading at 2019 levels
HUH????
a biotech company with a positive EBITDA not crazy multiples and a testing kit that does not need FDA approval
it is clearly working look at revenue growth, and before you talk about the loss relax they have tons of cash
second biggest ARKG holding and a two-ish year...
